Malignant Uveal Neoplasm

In patients with uveal melanoma, those with BAP1 expression (determined by immunohistochemical staining) had better survival.

PMID 25147369 · van Essen et al., 2014 · Open in CIViC

Somatic and germline BAP1 mutations are associated with uveal melanoma. In this preclinical study, gene set enrichment analysis revealed HDAC inhibitors as potential drugs in BAP1 mutant uveal melanom… (full text at CIViC)

PMID 22038994 · Landreville et al., 2012 · Open in CIViC

MEK inhibitor-resistant (selumetinib, PD0325901, GSK1129212) uveal melanoma cell lines were created from two GNAQ Q209L mutant cell lines. Overexpression of DDX43 mediated RAS-induced selumetinib resi… (full text at CIViC)

PMID 24899684 · Ambrosini et al., 2014 · Open in CIViC

EIF1AX was identified as a uveal melanoma (UM) driver gene by whole-exome sequencing. Approximately 14%–20% of UM carry a mutation in EIF1AX, with most mutations found in exons 1 and 2. EIF1AX mutatio… (full text at CIViC)

PMID 23793026 · Martin et al., 2013 · Open in CIViC

MEK inhibitors improve survival in cutaneous melanoma patients but show only modest efficacy in metastatic uveal melanoma patients. In this study, we screened for growth factors that elicited resistan… (full text at CIViC)

PMID 25952648 · Cheng et al., 2015 · Open in CIViC

In total, 77 patients with metastatic melanoma (62% cutaneous, 30% uveal, 8% mucosal) were admitted into a randomized phase II trial assessing the efficacy of Cabozantinib. Patients received cabozanti… (full text at CIViC)

PMID 28103611 · Daud et al., 2017 · Open in CIViC

Preclinical study in uveal melanoma cell lines. Cell lines (n=5) with GNAQ (92.1, Omm1.3, Mel270, Mel202) or GNA11 (Omm1) mutation were more sensitive to BRD4 inhibition with JQ1 than GNAQ/11 wild typ… (full text at CIViC)

PMID 26397223 · Ambrosini et al., 2015 · Open in CIViC

101 patients with metastatic uveal melanoma were randomized 1:1 to receive selumetinib or chemotherapy. Median PFS among patients randomized to chemotherapy was 7 weeks (95% CI, 4.3-8.4 weeks; median … (full text at CIViC)

PMID 24938562 · Carvajal et al., 2014 · Open in CIViC

Patients with metastatic melanoma (n=77; 48 cutaneous, 23 uveal, 6 mucosal) were enrolled in a phase II randomised discontinuation trial assessing cabozantinib. Patients received 100 mg cabozantinib d… (full text at CIViC)

PMID 28103611 · Daud et al., 2017 · Open in CIViC

Preclinical study in uveal melanoma cell lines. Cell lines (n=4) with GNAQ mutation (92.1, Omm1.3, Mel270, Mel202) were more sensitive to BRD4 inhibition with JQ1 than GNAQ/GNA11 wild type (n=3) cell … (full text at CIViC)

PMID 26397223 · Ambrosini et al., 2015 · Open in CIViC

Phase 1 study of MAPK1/2 inhibitor BAY 86-9766. 53 patients were evaluated for efficacy, one patients achieved a PR and 11 patients had stable disease. One ocular melanoma patient with prolonged stabl… (full text at CIViC)

PMID 23434733 · Weekes et al., 2013 · Open in CIViC

101 patients with metastatic uveal melanoma were randomized 1:1 to receive selumetinib or chemotherapy. Median PFS among patients randomized to chemotherapy was 7 weeks (95% CI, 4.3-8.4 weeks; median … (full text at CIViC)

PMID 24938562 · Carvajal et al., 2014 · Open in CIViC

In a cohort of 42 metastatic uveal melanoma patients treated with PD-1 inhibition, only one responded. A germline frameshift mutation in MBD4 was identified in this responder patient, with somatic los… (full text at CIViC)

PMID 29760383 · Rodrigues et al., 2018 · Open in CIViC

c-MET and ligand HGF were expressed by 6 uveal melanoma cell lines in-vitro. GNA-mutant cell lines (n=3) showed stronger expression of ligand and receptor as well as more receptor phosphorylation. SiR… (full text at CIViC)

PMID 24140933 · Surriga et al., 2013 · Open in CIViC

Preclinical study in uveal melanoma cell lines. c-MET was identified as a transcriptional target of miR-144. miR-144 was downregulated in 4 uveal melanoma cell lines and 5 human uveal melanoma tumor t… (full text at CIViC)

PMID 25961751 · Sun et al., 2015 · Open in CIViC